Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

October 23, 2019 1:14 AM UTC
Updated on Oct 23, 2019 at 1:19 AM UTC

Amgen Inc. (NASDAQ:AMGN) said EVP and CFO David Meline will retire at year end. The pharma hired Peter Griffith as EVP, finance and said he will succeed Meline as CFO on Jan. 1. Griffith was president of private equity firm Sherwood Canyon Group.

BlackThorn Therapeutics Inc. promoted co-founder William Martin to CEO and appointed him to the board. He was the company’s president and COO, as well as CSO. Prior to BlackThorn’s founding, he was executive director at Theravance Biopharma Inc. (NASDAQ:TBPH). BlackThorn is a computational sciences company developing therapies for neurobehavioral disorders...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article